Using The Quality by Design (QBD) Approach to Optimize Formulation for Rapid Migraine Relief

Objective Migraine is a complex neurological disorder that affects a significant portion of the global population. As traditional pharmacological approaches often fall short in alleviating symptoms, the development of innovative therapies has garnered significant interest. This text aims to summarize the current pharmacological options for managing migraine and to explore the potential impact of novel therapies. The concept of fast dissolving dosage form has become popular as new delivery system. Material and Methods: The formulations were prepared by solvent casting method and characterized using UV-visible spectroscopy, XRD, SEM, and FTIR. The RDF was prepared using a Quality by Design (QbD) approach for film optimization. Design of experiments and statistical analysis have been applied widely to formulation development, and are useful in process optimization and process validation. The optimized formulation was evaluated for folding endurance, disintegration time, and drug release. Stability studies were performed as per ICH guidelines. Results: Quality by Design (QbD) is a systematic and scientific approach that enhances product quality while ensuring the robustness and reproducibility of RDFs, as outlined in the Quality Target Product Profile (QTPP). DoE was integrated into the QbD framework to systematically evaluate the effects of predefined factors, particularly Critical Material Attributes (CMAs) and Critical Process Parameters (CPPS), on the desired responses (Critical Quality Attributes/CQA), ultimately leading to the identification of the optimal RDFs formulation. Conclusion: The integration of QbD and DoE, approaches holds significant potential in the development of RDFs. These strategies enable a more efficient, rational, and predictive formulation process. The drugs can be effectively incorporated in RDFs and can be a promising approach as a novel drug delivery system for promising therapeutic action.